



165 – 10551 Shellbridge Way
Richmond, BC, V6X 2W8

BIOMARK ANNOUNCES APPOINTMENT OF BILL GOOD

Vancouver, British Columbia – (November 12th, 2014)–BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) is pleased to announce that it has appointed Mr. Bill Good to its Advisory Board.

Veteran broadcaster Bill Good has done it all when it comes to media in Canada. Mr. Good spent fifty years on television and radio. For ten years, Mr. Good covered sports with CBC including Olympic and Commonwealth Games as well as Hockey night in Canada and co-hosted the famous Canada-Soviet hockey summit in 1972. Mr. Good left sports broadcasting in the late seventies and spent thirty years anchoring flagship early evening news at CBC, BCTV, and CTV all the while hosting the top rated Bill Good Show on CKNW.

Mr. Good has received many awards including the Lifetime Achievement Award from the Jack Webster Foundation, a Lifetime Achievement Award from Canada's News Directors and was recently awarded an Honorary Doctorate of Technology from BCIT.

Rashid Ahmed, President and CEO of BioMark, commented: “We are extremely proud that Bill Good has agreed to join our advisory board and I look forward to working with him in gaining media exposure for our new low cost cancer diagnostics technology. With his deep roots in Canada’s broadcast industry, we are confident Bill will provide valuable counsel as BioMark completes our Phase 3 Clinical Trials and enters the marketplace.

Bill Good, Media Advisory board, commented: “I'm pleased to join the knowledgeable and dynamic team of BioMark. It's an exciting time as the company moves into the third phase of clinical trials. And it's also exciting to think of the possibilities as BioMark continues with its ground breaking research towards early detection and treatment for cancers.”

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website www.thecse.ca.

For further information on BioMark, please Contact:

Rashid Ahmed Bux

President & CEO

BioMark Diagnostics Inc.

Tel. 604-282-6567

Email: info@biomarkdiagnostics.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of Biomark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved or disapproved the content of this press release.